DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cardene (Nicardipine Hydrochloride) - Summary

 
 



CARDENE SUMMARY

CARDENE®
(nicardipine hydrochloride)
CAPSULES

Cardene (nicardipine HCl) is a calcium ion influx inhibitor (slow channel blocker or calcium channel blocker).

CARDENE is indicated for the following:

I. Stable Angina

CARDENE is indicated for the management of patients with chronic stable angina (effort-associated angina). CARDENE may be used alone or in combination with beta-blockers.

II. Hypertension

CARDENE is indicated for the treatment of hypertension. CARDENE may be used alone or in combination with other antihypertensive drugs. In administering nicardipine it is important to be aware of the relatively large peak to trough differences in blood pressure effect (see DOSAGE AND ADMINISTRATION).


See all Cardene indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Cardene (Nicardipine)

Development of nicardipine prolonged-release implants after clipping for preventing cerebral vasospasm: from laboratory to clinical trial. [2013]
We have developed a drug delivery system using a vasodilating drug that can be implanted intracranially at the time of surgery for aneurysm clipping, without systemic side effects or side effects associated with long-term intrathecal drug administration.We have performed three studies (a single-center study with consecutive patients; a single-center, randomized, double-blind trial; and a multicenter cooperative study) and have proved that implantation of NPRIs reduces the incidence of cerebral vasospasm and DINDs and improves clinical outcome after SAH.

CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. [2011]
INTRODUCTION: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension... CONCLUSIONS: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.

Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]
INTRODUCTION: Various conservative treatments for Peyronie's disease (PD) have been attempted over the years. Intralesional verapamil injection has been tested in prospective randomized studies, but the effect of this treatment seems insufficient. Nicardipine is a calcium antagonist alternative to verapamil and is reportedly more effective in vitro. AIM: The objective of our study was to evaluate the usefulness of intralesional nicardipine injection as a conservative treatment for PD in the transition period of acute and chronic phase... CONCLUSION: Our findings indicate that intralesional nicardipine injection is clinically effective as a conservative treatment for PD in the transition period of acute and chronic phase. (c) 2010 International Society for Sexual Medicine.

Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. [2009.06]
BACKGROUND: Elevation in cardiac enzymes after percutaneous coronary intervention (PCI) is common and is associated with adverse clinical outcomes. HYPOTHESIS: Administration of intracoronary nicardipine-a calcium channel blocker will reduce cardiac enzyme levels in patients undergoing elective PCI... CONCLUSIONS: In low-risk patients undergoing elective PCI, intracoronary nicardipine administration did not produce a significant cardioprotective effect in reducing postprocedural cardiac enzymes leakage. Copyright (c) 2009 Wiley Periodicals, Inc.

Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy. [2009.05]
OBJECTIVES: To investigate the renoprotective effect of nicardipine in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALRP) in a prospective trial. Superior visualization of the increasingly performed RALRP requires pneumoperitoneum and extreme head-down tilt, both of which are associated with a decrease in postoperative renal function. Nicardipine causes preferential dilation of the renal arterioles and attenuates renal dysfunction after cardiac surgery... CONCLUSIONS: Continuous infusion of low-dose nicardipine during RALRP seems to offset the deleterious effects of inevitable pneumoperitoneum and extreme head-down tilt on renal function in preserving the eGFR and attenuating the development of renal insufficiency in the immediate postoperative period.

more studies >>

Clinical Trials Related to Cardene (Nicardipine)

Evaluation of IV Cardene(Nicardipine)and Labetalol Use in the Emergency Department [Recruiting]

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension [Recruiting]
To define the relationship between Cardene I. V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.

The Effect of Nicardipine on Kidney Function During Orthognathic Surgery Under Hypotensive Anesthesia [Not yet recruiting]
Since nicardipine is known to protect kidney function, nicardipine infusion will result in better renal parameters measured in this study.

NICardipine Neuroprotection in AortiC Surgery (NICNACS) [Not yet recruiting]
Objective

The objective of this study is to discover whether an infusion of nicardipine is able to reduce the time taken to achieve electrocerebral silence (ECS) during cardiopulmonary bypass (CPB) for aortic surgery.

Hypothesis

By inhibiting cold-induced cerebral vasoconstriction, nicardipine will maintain cerebral blood flow and allow more rapid cooling of the brain during CPB. This will manifest as a reduction in the time taken to achieve ECS and also as a reduction in overall CPB time.

IV Double and Triple Concentrated Nicardipine for Stroke and ICH [Recruiting]
Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.

more trials >>

Reports of Suspected Cardene (Nicardipine) Side Effects

Drug Interaction (2)Hypotension (2)Maternal Drugs Affecting Foetus (1)Anastomotic Leak (1)Aortitis Syphilitic (1)Medication Error (1)Aortic Arteriosclerosis (1)Aortic Dissection (1)Acute Respiratory Distress Syndrome (1)Post Procedural Haemorrhage (1)more >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014